CAR-T for lupus: the 'tip of the iceberg' for cell therapy in autoimmune disease
BioPharma
Stay updated with breaking news from Georg Schett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Worries about vaccine responsiveness relieved; Big Pharma gets interested
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the ...
New research at ACR Convergence 2023, the American College of Rheumatology's annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines.
Operator: Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Third Quarter 2023 Financial Results Conference Call and Business Update.